肿瘤治疗中止吐药物的研究进展  

Research progress of antiemetics in tumor therapy

作　　者：谭立君(综述)[1] 张大昕(审校)[1] 

机构地区：[1]哈尔滨医科大学附属第一医院肿瘤内科,150001

出　　处：《肿瘤研究与临床》2008年第12期859-861,共3页Cancer Research and Clinic

摘　　要：肿瘤患者化疗所致恶心、呕吐（CINV）是临床常见的不良反应。近年来由于对呕吐生理学的新认识，出现了5-HT3受体拮抗剂（5-HT3RA）、阿瑞吡坦（Aprepitant）和奥氮平（Olanzapine）新型止吐药物，使CINV得到了有效的控制，提高了化疗的耐受性，国际上许多肿瘤组织更新了各自制定和推荐的标准止吐方案。Chemotherapy plays a significant role in cancer therapy, but chemotherapy-induced nausea and vomiting（CINV） common happened and affects patients satisfaction with treatment. With the development of physiology on emesis, the new antiemetics such as 5-HT3 receptor antagonist （5-HT3RA）, Aprepitant and Olanzapine greatly improved the control of CINV, the guidelines for antiemetics were defined. Research progress of antiemetics was summarized.

关 键 词：止吐药 肿瘤 研究 

分 类 号：R735.4[医药卫生—肿瘤]